Chemokine Receptor Inhibitor vMIP-II Promoting Lymphocytes in COVID-19 Patients and Its Related Mechanism In Vitro

Shiyu Li, Yuzhe Wang, Lixia Feng, Zhenyou Jiang, Feng Cong, Youyu Chen, Zhenning Dai, Shuting Liu, Shitao Zhu, Zhengbin Fei, Yichao Xu, Xuemei Mo, Shanshan Shi, Xiao Zheng, Anding Xu, Yong Gao, Wenhua Huang, Nuofu Zhang, Hanxiao Sun

Like Comment

Received Date: 3rd May 20

Coronavirus disease (COVID-19) accompanies severe immune injury as well as a decrease and overactivation of T lymphocytes. We observed that vMIP-Ⅱ, a broad-spectrum chemokine receptor inhibitor, could improve the lymphocyte decrease of COVID-19. Comparisons of T cell populations in PBMCs showed that the effects of vMIP-II on the subsets of T cells and cytokine secretion stimulated by SARS-CoV-2 S protein were the same as those in the asymptomatic infection group: the proportion of CD8+ TCM cells in the vMIP-II treatment and asymptomatic groups was significantly higher than that in the symptomatic control group. Differential gene expression of effector CD8+ T cells suggested that vMIP-II inhibits multiple chemokine receptors and related signal pathway and strengthens their stem proliferating capacity. Thus, vMIP-II reconstitutes cellular immunity lost due to acute infection of SARS-CoV-2 by modulating effector CD8+ T cells to produce more TCM cells.

Read in full at Research Square.

This is an abstract of a preprint hosted on an independent third party site. It has not been peer reviewed but is currently under consideration at Nature Communications.

Go to the profile of Nature Communications

Nature Communications

Nature Research, Springer Nature